1. Low- vs. Middle-dose Total Skin Electron Beam Therapy for Mycosis Fungoides: An Efficiency-based Retrospective Survey of Skin Response
- Author
-
Aurélie Du-Thanh, M. Charissoux, Christine Kerr, Annelies Taverniers, Olivier Dereure, Pathogénèse et contrôle des infections chroniques (PCCI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Montpellier (CHU Montpellier )-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque, and Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Skin Neoplasms ,[SDV]Life Sciences [q-bio] ,total skin electron beam therapy ,Electrons ,Dermatology ,middle dose ,Gastroenterology ,Disease-Free Survival ,030207 dermatology & venereal diseases ,03 medical and health sciences ,Total skin electron beam therapy ,0302 clinical medicine ,Retrospective survey ,Internal medicine ,medicine ,Humans ,Adverse effect ,ComputingMilieux_MISCELLANEOUS ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Mycosis fungoides ,mycosis fungoides ,business.industry ,Skin response ,Significant difference ,Low dose ,Radiotherapy Dosage ,General Medicine ,Middle Aged ,medicine.disease ,3. Good health ,Treatment Outcome ,low dose ,Median time ,RL1-803 ,030220 oncology & carcinogenesis ,Female ,Neoplasm Recurrence, Local ,business - Abstract
Optimal doses of total skin electron beam therapy for mycosis fungoides remain to be established. Clinical efficiency and adverse effects of middle-dose (25 Gy) vs. low-dose (10-12 Gy) total skin electron beam therapy were retrospectively compared in a series of 14 and 12 mycosis fungoides, respectively. Overall skin response rate was 96.2% (92.9% middle-dose and 100% low-dose; not significant (NS)). Overall complete and partial skin response rates were 57.7% (42.9% middle-dose and 75% low-dose; NS) and 38.5% (50% middle-dose and 25% low-dose; NS), respectively. All responding patients relapsed after an overall median time of 5 months (7 months middle-dose vs. 4 months low-dose; p = 0.164, NS). Tolerance was equally fair in both groups, with only grade 1 and 2 adverse events observed in 100% vs. 66.7% of patients in middle-dose and low-dose groups (NS). Although no significant difference was observed, middle-dose protocol may be recommended owing to a longer relapse-free survival for a similar tolerance.
- Published
- 2019
- Full Text
- View/download PDF